ClearPoint Neuro Inc vs The Coca-Cola Co K — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while The Coca-Cola Co K trades at $86.54 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 841.5× ClearPoint Neuro Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | KO | |
|---|---|---|
Market Cap | $444.14M | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $89.08 |
52-Week Low | $8.66 | $65.67 |
Enterprise Value | $478.72M | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →